LONDON, UK: Apogee Therapeutics LLC has completed $149 million Series B financing round. RTW Venture Fund, alongside other investment vehicles of RTW Investments LP participated in the Series B financing round together with other investors.

Apogee Therapeutics is a privately held pre-clinical stage biotech advancing potentially best-in-class therapies for immunological and inflammatory disorders. The company is building a pipeline of product candidates targeting clinically validated biology and well-established development pathways.

Through a strategic partnership with Paragon Therapeutics, Apogee has the option for exclusive development and commercial rights to a suite of antibodies which have been specifically engineered to target immunological and inflammatory disorders. Its lead program, APG777, is expected to enter clinical trials in 2023.

Joshua Kennedy-Smith, PhD, Managing Director at the Investment Manager, will participate in meetings of Apogee’s board of directors in an observer capacity. He said:

“We are excited to co-lead Apogee’s Series B financing and to support its efforts to develop potentially best-in-class immunological therapies. The addition of Apogee to RTW Venture Fund’s portfolio further expands our focus on inflammatory disease with high unmet need and investing in innovative therapeutic modalities.”

The Investment Manager is looking forward to growing the Company’s investment pipeline and updating shareholders on further investments by the Company in due course.